Prosecution Insights
Last updated: November 04, 2026
Application No. 18/518,560

TGF-BETA THERAPEUTICS FOR AGE DISEASE

Non-Final OA §102§103§112§DOUBLEPATENT
Filed
Nov 23, 2023
Priority
May 24, 2021 — provisional 63/192,175 +2 more
Examiner
POLIAKOVA-GEORGAN, EKATERINA
Art Unit
1637
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Gmp Biotechnology Limited
OA Round
1 (Non-Final)
64%
Grant Probability
Moderate
1-2
OA Rounds
0m
Est. Remaining
82%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
440 granted / 690 resolved
+3.8% vs TC avg
Strong +18% interview lift
Without
With
+18.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
58 currently pending
Career history
763
Total Applications
across all art units

Statute-Specific Performance

§101
6.9%
-33.1% vs TC avg
§103
27.7%
-12.3% vs TC avg
§102
19.2%
-20.8% vs TC avg
§112
27.1%
-12.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 690 resolved cases

Office Action

§102 §103 §112 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s species election of severe respiratory disease due to viral infection and antisense oligonucleotide in the reply filed on 08/03/2026 is acknowledged. Claims 10, 11, 21-24 are withdrawn as being drawn to nonelected species. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1, 5-9, 13-16, 20, 30, 33, 36 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Claims are broadly drawn to treatments or amelioration of the symptoms of age disease, such disease can be long term coronavirus disease, hyperinflammatory immune disease, severe respiratory disease due to viral infection, age-related fibrotic disease or age-related cancer. Instant claims encompass treatment of vaguely defined genus of age diseases. Instant specification broadly defines age disease as disease or condition “which follow later in time after an earlier disease or condition, or during or after a disease having long lasting symptoms or effects, or diseases or conditions which follow after long lasting symptoms of an earlier condition have ceased. Later in time can be relatively short, such as days, or relatively long, such as years or decades” (see paragraph [0010]). Such definition can be applied to essentially any disease which happen to be diagnosed at later age. Further, specification does not define exactly what age is the late age. Thus the genus of age diseases encompass any possible disease that can happen to any person at any age. Specification provides specific examples of age diseases such as be long term coronavirus disease, hyperinflammatory immune disease, severe respiratory disease due to viral infection, age-related fibrotic disease or age-related cancer (see paragraph [0022]). Again, there is no definition of what age the disease has to be related to be “age-related”. For example, if someone is diagnosed with colon cancer at age 25, is the disease age related? Again, the genus of age-related diseases encompasses essentially any disease at any age. The genus of age diseases encompasses a large number of all possible diseases and one of skilled in the art cannot reliably predict which disease can be treated by instantly claimed methods, and which can not. There is no description of the necessary and sufficient elements of the species encompassed by the breadth of the claims. The only species described in specification are long term coronavirus disease, hyperinflammatory immune disease, severe respiratory disease due to viral infection, age-related fibrotic disease or age-related cancer. Applicant fails to describe representative members of Applicant's broadly claimed genus. One of the skill in the art would not recognize that Applicant was in possession of the necessary common attributes or features of the genus in view of the disclosed species. Since the disclosure fails to describe the common attributes that identify members of the genus, and because the genus is highly variant, long term coronavirus disease, hyperinflammatory immune disease, severe respiratory disease due to viral infection, age-related fibrotic disease or age-related cancer are not sufficient to describe the claimed genus. Therefore, given the lack of written description in the specification with regard to the structural and functional characteristics of the claimed compositions, it is not clear that Applicant was in possession of the claimed genus at the time this application was filed. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 13, 20 and 33 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 13 comprises abbreviations such as Sompraz D, Zifi CV/Zac D, CCM and others, which full names and definitions are not present in the claims or disclosure. Thus, metes and bounds of claim 13 are undefined. Claims 20 and 33 recite antisense oligonucleotides of SEQ ID NOs: 1-9, which are TGF-β2-specific. Sequence search shows that at least SEQ ID NOs: 1-7 are SARS-CoV-2 specific, thus they are not TGF-β2-specific. Inclusion of those sequences in the claims makes their metes and bounds unclear. To overcome the rejection it is suggested to exclude any sequences which are not specific for TGF-β2. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1, 5-6, 13-16, 36 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Chen (Int J Biol Sci, April 2020, vol.16, pages 1954-1955). Concerning claims 1 and 5-6 Chen disclose treatment of consequences of COVID-19, which is well known coronavirus, such as acute respiratory distress syndrome and cytokine storm (see first column on page 1954), by administering TGF-β antibodies or other TGF-β inhibitors (see “Proposed Therapy” section on page 1955) to prevent fibrosis of lungs in human patients (see “Therapeutic goal” section on page 1955). The term “age disease” of claim 1 is interpreted as a disease happening at any age as a consequence of COVID-19 (see written description rejection above). Such acute respiratory distress syndrome is a severe respiratory disease, which leads to fibrosis in lungs (see first column on page 1954). Concerning claim 13 Chen disclose administration of anti-inflammatory compounds for treatment as well (see Section “Design of the clinical trials” on page 1955). Concerning claims 14-16 the effects recited in the claims are expected to happen upon practicing method of claim 1 in the absence of evidence to the contrary. Concerning claim 36 Chen disclose treatment as above to improve symptoms of cytokine storm (see first column on page 1954). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1, 5-7, 13-16, 36 is/are rejected under 35 U.S.C. 103 as being unpatentable over Chen, above, as applied to claims 1, 5-6, 13-16, 36, and in further view of Newberry et al (US 2020/0253562, August 2020). Teachings of Chen are discussed above. Chen do not teach treatment of subjects with COVID-19 hospitalized with or without oxygen therapy. Newberry teach that subjects with COVID-19 can be hospitalized with or without oxygen therapy (see paragraph [0291]). It would have been obvious to one of the ordinary skill in the art before the effective filing date of the claimed invention to treat subjects with COVID-19 hospitalized with or without oxygen therapy as taught by Newberry by methods taught by Chen, arriving at instant invention. One of the ordinary skill in the art would be motivated to do so because Chen teach methods of treatment of consequences of COVID-19 and Newberry describes a subpopulation of patients with COVID-19, who can be treated by method taught by Chen with reasonable expectation of success. Claim(s) 1, 5-6, 8-9, 13-16, 36 is/are rejected under 35 U.S.C. 103 as being unpatentable over Chen, above, as applied to claims 1, 5-6, 13-16, 36, and in further view of Shibata et al (Hypertension research, July 2020, 43: 1028-1046) and Nagourney et al (US 2020/0386766, December 2020). Teachings of Chen are discussed above. Chen do not teach treatment of subjects older than 60 years with COVID-19 hospitalized and with hypertension or exhibiting low PaO2 less than 77 mmHg. Shibata teach that subjects older than 60 years with COVID-19 can be hospitalized with hypertension comorbidity (see second column on page 1029). Nagourney teach that patients with COVID-10 with PaO2 less than 75 mmHg are high risk (see paragraph [0178]). It would have been obvious to one of the ordinary skill in the art before the effective filing date of the claimed invention to treat hospitalized subjects older than 60 years old and with hypertension with COVID-19 or with PaO2 less than 75 mmHg as taught by Shibata and Nagourney by methods taught by Chen, arriving at instant invention. One of the ordinary skill in the art would be motivated to do so because Chen teach methods of treatment of consequences of COVID-19 and Shibata and Nagourney describe subpopulations of patients with COVID-19, who can be treated by method taught by Chen with reasonable expectation of success. Claim(s) 1, 5-6, 13-16, 20, 30, 33, 36 is/are rejected under 35 U.S.C. 103 as being unpatentable over Chen, above, as applied to claims 1, 5-6, 13-16, 36, and in further view of Trieu (US 2017/0226518, August 2017). Teachings of Chen are discussed above. Chen do not teach treatment of subjects with COVID-19 by administering antisense oligonucleotide of instant SEQ ID NO: 9 targeting TGF-β2 with specific dosage and prepared from lyophilized powder. Trieu teach TGF-β inhibitors such as antibodies and antisense oligonucleotides for disease treatment (see paragraphs [0008-0010]). One of such antisense oligonucleotides is trabedersen of SEQ ID NO: 1, identical to instant SEQ ID NO: 9 (see paragraph [0048]). Trieu teach that antisense oligonucleotide can be prepared from lyophilized powder (see paragraphs [0081-0082]). Trieu teach optimization of antisense oligonucleotide dosage (see paragraphs [0052, 0099]). It would have been obvious to one of the ordinary skill in the art before the effective filing date of the claimed invention to treat subjects with COVID-19 by administering antisense oligonucleotide of instant SEQ ID NO: 9 taught by Trieu instead of antibody taught in the methods of Chen, arriving at instant invention. One of the ordinary skill in the art would be motivated to do so because Chen teach methods of treatment of consequences of COVID-19 by administering antibody targeting TGF-β and Trieu teach other inhibitors of TGF-β such as antisense oligonucleotide of instant SEQ ID NO: 9, making it obvious to use such oligonucleotide instead of antibody, because they both serve the same function, inhibition of TGF-β. Further, it would be a matter of ordinary optimization to identify specific dosing of antisense oligonucleotide based on teachings of Trieu. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1, 5-6, 20, 30, 33 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-7 of U.S. Patent No. 9,758,786. Although the claims at issue are not identical, they are not patentably distinct from each other because claims from ‘786 are drawn to treatment of pancreatic cancer, which satisfies broadest reasonable interpretation of an age disease of instant claims, by administering of trabedersen, which is antisense oligonucleotide of instant SEQ ID NO: 9. Claims 1, 5-6, 20, 30, 33 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-11 of U.S. Patent No. 9,963,703. Although the claims at issue are not identical, they are not patentably distinct from each other because claims from ‘703 are drawn to treatment of pancreatic cancer, which satisfies broadest reasonable interpretation of an age disease of instant claims, by administering of trabedersen, which is antisense oligonucleotide of instant SEQ ID NO: 9. Claims 1, 5-9, 13-16, 20, 30, 33, 36 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 80, 83, 87 of copending Application No. 17/946,578 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because claims from ‘578 recite treatment of cytokine storm in a viral disease due to SARS-CoV-2 by administering antisense oligonucleotide identical to instant SEQ ID NO: 9. Such cytokine storm satisfies broadest reasonable interpretation of an age disease of instant claims. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to EKATERINA POLIAKOVA whose telephone number is (571)270-5257. The examiner can normally be reached Mon-Fri 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jennifer Dunston can be reached at (571)272-2916. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /EKATERINA POLIAKOVA-GEORGANTAS/Primary Examiner, Art Unit 1637
Read full office action

Prosecution Timeline

Nov 23, 2023
Application Filed
Oct 15, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12781274
Novel Replicase Cycling Reaction (RCR) and the Related RdRP-Binding Site Designs Thereof
3y 1m to grant Granted Nov 03, 2026
Patent 12781232
BACTERIAL CONTINUOUS EVOLUTION SYSTEM, ORTHOGONAL ERROR-PRONE DNA POLYMERASE, AND CONTINUOUS EVOLUTION METHOD
2y 11m to grant Granted Nov 03, 2026
Patent 12774310
POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS
3y 5m to grant Granted Oct 27, 2026
Patent 12767946
OLIGONUCLEOTIDES FOR TISSUE SPECIFIC APOE MODULATION
6y 7m to grant Granted Oct 20, 2026
Patent 12735705
COMPOUND, METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING EXPRESSION OF ATAXIN 3
3y 10m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
64%
Grant Probability
82%
With Interview (+18.3%)
2y 7m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 690 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month